Neuroimmune Dysfunction in Frontotemporal Dementia

Migration, Crosslink

📖

Neuroimmune Dysfunction in Frontotemporal Dementia

active

wiki page Created: 2026-04-02T07:19:49 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-neuroimmune-dysfunction-

📖 Wiki Page

mechanism2778 wordssynced 2026-04-02

Neuroimmune Dysfunction in Frontotemporal Dementia

Overview

Neuroimmune dysfunction has emerged as a central pathogenic mechanism across all subtypes of [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD), extending beyond a simple reactive response to neurodegeneration and instead representing a primary driver of disease progression[@chen2023]. The FTD brain exhibits robust activation of microglia and astrocytes, dysregulated complement pathways, elevated pro-inflammatory cytokine profiles, and disruption of the blood-brain barrier (BBB) — collectively creating a neurotoxic microenvironment that accelerates synaptic loss, neuronal death, and disease progression[@liddell2019].

Unlike [Alzheimer's disease](/diseases/alzheimers-disease) where neuroinflammation has been extensively studied, FTD-associated neuroimmune dysfunction has only recently received systematic investigation. However, evidence from postmortem studies, PET imaging with translocator protein (TSPO) ligands, fluid biomarker analysis, and single-cell transcriptomics has converged on a consistent picture: microglial-mediated neuroinflammation is pervasive across FTD subtypes and represents both a promising biomarker and a tractable therapeutic target[@heneka2015][@gomez2020].

The Microglial Landscape in FTD

Microglial Activation States

...

Neuroimmune Dysfunction in Frontotemporal Dementia

Overview

Neuroimmune dysfunction has emerged as a central pathogenic mechanism across all subtypes of [frontotemporal dementia](/diseases/frontotemporal-dementia) (FTD), extending beyond a simple reactive response to neurodegeneration and instead representing a primary driver of disease progression[@chen2023]. The FTD brain exhibits robust activation of microglia and astrocytes, dysregulated complement pathways, elevated pro-inflammatory cytokine profiles, and disruption of the blood-brain barrier (BBB) — collectively creating a neurotoxic microenvironment that accelerates synaptic loss, neuronal death, and disease progression[@liddell2019].

Unlike [Alzheimer's disease](/diseases/alzheimers-disease) where neuroinflammation has been extensively studied, FTD-associated neuroimmune dysfunction has only recently received systematic investigation. However, evidence from postmortem studies, PET imaging with translocator protein (TSPO) ligands, fluid biomarker analysis, and single-cell transcriptomics has converged on a consistent picture: microglial-mediated neuroinflammation is pervasive across FTD subtypes and represents both a promising biomarker and a tractable therapeutic target[@heneka2015][@gomez2020].

The Microglial Landscape in FTD

Microglial Activation States

Microglia — the brain's resident immune cells — adopt diverse activation states in FTD that go beyond the classical M1 (pro-inflammatory) and M2 (anti-inflammatory) dichotomy. Single-cell transcriptomic studies of postmortem FTD brain tissue have identified at least four distinct microglial states associated with disease[@milller2023]:

Homeostatic microglia (CX3CR1+, P2RY12+, TMEM119+) — reduced in number and transcriptional signature in FTD brains, particularly in GRN-FTD[@pariker2020]

DAM (disease-associated microglia) — upregulate Cd11c, ApoE, and lipid metabolism genes; these may represent an attempt at neuroprotection that is ultimately insufficient

pro-inflammatory microglia — characterized by elevated IL1B, TNF, CCL2, and NLRP3 inflammasome components

neurodegeneration-associated microglia (NAM) — express Lyz2, Itgax, and genes involved in phagocytosis, but with pro-apoptotic signaling

The loss of homeostatic microglial identity and gain of disease-associated transcriptional programs correlates with clinical severity and neuropathological burden in FTD[@zhou2022].

TREM2 in FTD Microglial Dysfunction

TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) plays a critical role in microglial function, serving as a sensor of lipid debris and damaged neurons that promotes microglial survival, proliferation, and phagocytosis. TREM2 deficiency in FTD models leads to:

Reduced microglial surveillance of synaptic elements[@key2015]
Increased synaptic pathology and aberrant connectivity[@zhang2014]
Impaired clearance of aggregate-prone proteins
Enhanced neurotoxicity from extracellular debris

Loss-of-function variants in TREM2 are associated with increased risk for multiple neurodegenerative diseases, and reduced TREM2 signaling is observed in sporadic FTD cases. In GRN-FTD specifically, progranulin deficiency impairs TREM2 signaling pathways, reducing microglial phagocytic capacity and driving a switch toward a pro-inflammatory phenotype[@liddell2019a].

Microglial Synaptic Pruning in FTD

A landmark finding connecting microglial dysfunction to FTD pathogenesis is the discovery of complement-mediated synaptic pruning as a driver of early synaptic loss in genetic FTD. In both [GRN](/genes/grn)-associated FTD and [C9orf72](/genes/c9orf72)-associated FTD, complement component C1q and C3 are upregulated at synapses, marking them for microglial elimination via complement receptor 3 (CR3)[@sudomino2023].

This excessive synaptic pruning occurs early in disease — before overt neuronal loss — and correlates with the cognitive and behavioral decline seen clinically. The mechanism involves:

Astrocyte dysfunction: Progranulin-deficient astrocytes release reduced levels of C1 inhibitor, allowing complement activation at synapses

Microglial CR3 engagement: Activated microglia phagocytose C1q/C3-tagged synapses through CR3

Synaptic loss: The net effect is progressive synapse elimination that outpaces synaptic formation, leading to net synaptic decline[@sudomino2023a]

This mechanism links the three major genetic forms of FTD through a convergent pathway: GRN mutations impair progranulin-mediated regulation of complement, C9orf72 expansions dysregulate microglial immune responses, and MAPT pathology triggers complement activation through neuronal stress.

Complement System Dysregulation

Complement Cascade in the FTD Brain

The complement system — a critical component of innate immunity — is dramatically dysregulated in FTD brain tissue[@williams2023]. Postmortem studies reveal:

| Complement Component | Change in FTD | Cellular Source | Effect |
|---------------------|---------------|-----------------|--------|
| C1q (classical pathway initiator) | Strongly upregulated | Astrocytes, neurons | Synapse tagging, microglial recruitment |
| C3 (central component) | Upregulated | Astrocytes, microglia | Opsonization of synapses |
| C4 (classical pathway) | Upregulated | Astrocytes | Enhanced complement activation |
| C1QA, C1QB genes | Upregulated (RNA) | Astrocytes | Synapse elimination |
| C3aR (receptor) | Elevated | Neurons, microglia | Pro-inflammatory signaling |
| C5aR (receptor) | Elevated | Neurons | Neurotoxicity |

Complement deposition on synapses is detectable in all FTD subtypes — including sporadic FTD — but is most pronounced in genetic forms[@sudomino2023]. Cryo-EM studies of FTD brain tissue show C1q bound to presynaptic terminals, where it initiates the complement cascade leading to microglial engulfment.

Therapeutic Implications of Complement Dysregulation

The complement-synapse connection offers several therapeutic strategies:

Anti-C1q antibodies (e.g., ANX-005) are in clinical development to block complement-mediated synapse loss
C3 inhibitors (e.g., pegcetacoplan) have shown benefit in preclinical FTD models
Neuronal C3aR blockade may reduce neurotoxic complement signaling

A 2024 study demonstrated that inhibiting complement C1q in a mouse model of FTD rescued synaptic density, reduced microglial activation, and improved behavioral outcomes — providing proof-of-concept for complement targeting in FTD[@sudomino2023].

Astrocyte Dysfunction

Reactive Astrogliosis in FTD

Astrocytes undergo profound changes in FTD, transitioning from their normal homeostatic functions to reactive states that can be both protective and destructive[@erlich2023]. Key changes include:

Upregulation of GFAP (glial fibrillary acidic protein): A hallmark of astrogliosis, GFAP is strongly upregulated in FTD frontal and temporal cortex. The degree of GFAP elevation correlates with neuropathological severity.

Loss of glutamate transporters: EAAT1 (GLAST) and EAAT2 (GLT-1) are downregulated in FTD brains, leading to impaired glutamate clearance and excitotoxic stress. This is particularly pronounced in [TDP-43 pathology](/mechanisms/ftd-tdp-pathology) subtypes.

Dysregulated potassium buffering: Kir4.1 channel dysfunction in reactive astrocytes impairs potassium homeostasis, contributing to neuronal hyperexcitability.

Altered metabolic support: FTD astrocytes show reduced lactate production and metabolic coupling with neurons, compromising energy support.

Complement factor production: Astrocytes in FTD become major producers of complement components (C1q, C3, C4), driving complement-mediated synaptic loss as described above.

Astrocyte-Neuron Metabolic Coupling

The breakdown of astrocyte-neuron metabolic coupling in FTD contributes to disease progression through multiple mechanisms. Normally, astrocytes provide lactate to neurons as an energy substrate, particularly during periods of high neuronal activity. In FTD, this coupling is disrupted, leading to:

Reduced neuronal ATP levels
Impaired clearance of extracellular potassium
Accumulation of extracellular glutamate (excitotoxicity)
Compromised antioxidant defense (reduced glutathione production)

Cytokine and Chemokine Profile in FTD

Peripheral and CNS Cytokine Levels

Systematic meta-analyses of cytokine profiles in FTD reveal distinct patterns compared to healthy aging and [Alzheimer's disease](/diseases/alzheimers-disease)[@chen2020]:

Elevated in FTD:

IL-6 (interleukin-6): Strongly elevated in both CSF and plasma, correlates with disease severity
TNF-alpha (tumor necrosis factor): Elevated in plasma and brain tissue
IL-1beta: Elevated in CSF, particularly in GRN-FTD
CCL2 (MCP-1): Elevated in CSF, attracts monocytes/microglia
CXCL10 (IP-10): Elevated in CSF, associated with TDP-43 pathology

Elevated in AD (distinguishing from FTD):

IL-10: Higher in AD than FTD
TGF-beta: Elevated in AD, may reflect amyloid-driven anti-inflammatory response

No significant change in FTD:

IL-4, IL-13: T-helper type 2 cytokines relatively spared

This cytokine signature suggests that FTD is characterized by a predominantly pro-inflammatory (M1-like) immune response, whereas AD shows a mixed profile with stronger anti-inflammatory components.

NLRP3 Inflammasome Activation

The NLRP3 inflammasome — a multiprotein complex that activates caspase-1 and drives maturation of IL-1beta and IL-18 — is activated in FTD brain tissue. Activation is observed particularly in:

[GRN](/genes/grn)-associated FTD (progranulin deficiency dysregulates lysosomal pathways that activate NLRP3)
Sporadic FTD with TDP-43 pathology
C9orf72-associated FTD (DPR toxicity activates inflammasome)

NLRP3 activation creates a vicious cycle: IL-1beta release promotes microglial activation, which in turn produces more IL-1beta. This feed-forward loop drives chronic neuroinflammation.

Blood-Brain Barrier Dysfunction

BBB Disruption in FTD

Evidence for blood-brain barrier (BBB) dysfunction in FTD comes from multiple sources[@sweeney2018][@boza2019]:

Imaging studies: Dynamic contrast-enhanced MRI reveals BBB leakage in the frontal and temporal cortex of FTD patients, particularly in [bvFTD](/diseases/behavioral-variant-ftd) cases. The degree of leakage correlates with disease duration and severity.

CSF biomarkers of BBB disruption:

Elevated albumin quotient (CSF albumin/serum albumin) indicates serum protein leakage
Elevated fibrinogen and immunoglobulin levels in CSF
Reduced levels of BBB-specific transport proteins

Postmortem findings:

Loss of pericytes and perivascular macrophages
Reduced expression of tight junction proteins (claudin-5, occludin)
Extravasation of serum proteins (fibrinogen, IgG) into brain parenchyma

Cellular mechanisms:

Pro-inflammatory cytokines (TNF-alpha, IL-6) directly disrupt tight junction integrity
VEGF overexpression contributes to vascular permeability
Pericyte dysfunction from progranulin deficiency impairs BBB maintenance in GRN-FTD

Perivascular Immune Cell Infiltration

BBB dysfunction allows peripheral immune cells — particularly monocytes and T-lymphocytes — to enter the CNS parenchyma. While the full significance of this infiltration is still being characterized, evidence suggests:

CD8+ T-cells accumulate around blood vessels in FTD brains and may contribute to cytotoxic damage
Monocytes recruited into the CNS differentiate into macrophage-like cells that contribute to neuroinflammation
Regulatory T-cells (Tregs) are reduced in FTD peripheral blood, potentially reducing anti-inflammatory control

Neuroinflammation Across FTD Genetic Subtypes

GRN (Progranulin) Mutations

[GRN](/genes/grn)-associated FTD represents the clearest link between a specific genetic mutation and neuroimmune dysfunction[@liddell2019a]. Progranulin is:

Secreted by microglia and neurons to regulate inflammatory responses
A direct regulator of complement activation (binds to C1q, inhibits classical complement pathway)
Required for proper microglial lysosomal function and phagocytosis
A ligand for TREM2, linking it to microglial survival and function

Loss of progranulin leads to:

Hyperactive microglia: Increased baseline activation and exaggerated responses to stimuli
Complement dysregulation: Uninhibited complement attack on synapses
Lysosomal dysfunction: Accumulation of undigested material, NLRP3 inflammasome activation
Impaired debris clearance: Synapses and protein aggregates accumulate

C9orf72 Repeat Expansions

[C9orf72](/genes/c9orf72) is highly expressed in microglia, where it regulates inflammatory responses. Expansion carriers show:

Increased baseline microglial activation (detectable in presymptomatic carriers on TSPO-PET)
Enhanced response to immune stimuli: C9orf72-deficient microglia show exaggerated TNF-alpha and IL-6 production
Altered complement regulation: Impaired regulation of complement factor production
Immune cell infiltration: Enhanced peripheral monocyte recruitment to the CNS

MAPT Mutations

[MAPT](/genes/mapt)-associated FTD and related tauopathies show distinct neuroimmune signatures:

Microglial proliferation driven by tau pathology signals (e.g., extracellular tau aggregates)
NLRP3 inflammasome activation from tau-mediated mitochondrial dysfunction and ROS production
Complement activation at synapses and myelin sheaths
Astrocyte reactivity with altered glutamate transport and metabolic support

The relationship between tau pathology and neuroinflammation is bidirectional: tau aggregates activate microglia, and microglial-released inflammatory mediators (IL-1beta, TNF-alpha) promote further tau phosphorylation and aggregation, creating a self-reinforcing cycle.

FUS Mutations

[FUS](/genes/fus)-associated FTD shows:

RNA-binding protein dysregulation in glia: FUS is expressed in astrocytes and microglia; mutant FUS may affect glial RNA processing
Stress granule formation in glia: Mutant FUS accumulates in astrocytic stress granules, disrupting RNA homeostasis
Impaired astrocyte support function: FUS pathology in astrocytes reduces their neuroprotective capacity
Microglial activation: Reactive microglia are observed in FUS-FTD brain tissue

Neuroimmune Mechanisms: Pathway Diagram

Mermaid diagram (expand to render)

Biomarkers of Neuroimmune Dysfunction

PET Imaging

TSPO-PET (translocator protein positron emission tomography) provides in vivo measurements of microglial activation. TSPO is upregulated in activated microglia and is detectable using radioligands such as [^11C]-PK11195, [^18F]-DPA-714, and [^11C]-ER176.

Studies show:

Elevated TSPO binding in frontal and temporal cortex in bvFTD patients vs. controls
Higher TSPO signal in GRN-FTD and C9orf72-FTD vs. sporadic FTD
TSPO signal correlates with disease severity and progression rate
Presymptomatic carriers show elevated TSPO, enabling early detection of immune activation

Fluid Biomarkers

| Biomarker | Source | Change in FTD | Significance |
|-----------|--------|--------------|--------------|
| NfL (neurofilament light) | CSF/plasma | Elevated | Marker of neuronal damage, disease progression |
| GFAP (glial fibrillary acidic protein) | Plasma | Elevated | Astrocyte reactivity |
| YKL-40 (chitinase-3-like protein 1) | CSF | Elevated | Microglial activation |
| sTREM2 (soluble TREM2) | CSF | Reduced in GRN-FTD | Impaired microglial TREM2 signaling |
| IL-6 | CSF/plasma | Elevated | Systemic and CNS inflammation |
| TNF-alpha | Plasma | Elevated | Pro-inflammatory state |
| MCP-1/CCL2 | CSF | Elevated | Monocyte recruitment |
| C1q | CSF | Elevated | Complement activation at synapses |
| C3b/iC3b | CSF | Elevated | Complement pathway activation |

Therapeutic Strategies Targeting Neuroimmune Dysfunction

Complement Inhibitors

Anti-C1q therapy (ANX-005, annexon Biosciences):

Binds C1q, blocking classical complement pathway activation
Prevents complement-mediated synapse loss in GRN-FTD models
Phase 1/2 trial in GRN-FTD showing acceptable safety and biomarker effects

C3 inhibitors (pegcetacoplan, avacopan):

Block central complement component C3
Prevent all downstream complement effector functions
Preclinical evidence for neuroprotection in FTD models

Microglial Modulation

TREM2 agonism:

TREM2-activating antibodies (AL002) promote microglial survival and phagocytosis
Enhances clearance of debris and aggregate-prone proteins
In clinical trials for Alzheimer's disease; potential for FTD

CSF1R inhibitors (to block microglial proliferation):

Prevent disease-associated microglial expansion
In preclinical development for FTD

Anti-inflammatory Approaches

Minocycline: Antibiotic with anti-inflammatory properties; limited efficacy in FTD clinical trials to date.

TNF-alpha inhibitors: Etanercept and similar biologics have been explored; BBB penetration is a challenge.

NSAIDs: Observational studies suggest reduced FTD risk with long-term NSAID use, but clinical trials have not confirmed benefit.

Astrocyte-Targeted Therapies

EAAT2 (GLT-1) upregulation via ceftriaxone has been explored but showed no benefit in ALS trials; potential for FTD.

Metabolic coupling enhancement via lactate supplementation or astrocyte metabolic modulators is in preclinical development.

Research Gaps

Cell-type specificity: Which immune cell type (microglia, astrocytes, peripheral monocytes, T-cells) is the primary driver of neuroinflammation in each FTD subtype?

Temporal dynamics: When does neuroimmune dysfunction begin relative to protein aggregation and synaptic loss? Does it precede clinical symptoms?

Microglial states: How do disease-associated microglial states evolve over time, and which are therapeutically targetable?

BBB restoration: Can BBB function be restored after dysfunction begins, or must interventions be preventive?

Peripheral-central immune link: What is the role of peripheral immune system changes (altered monocyte function, reduced Tregs) in CNS neuroinflammation?

Sex differences: Are there sex differences in neuroimmune responses that explain the higher prevalence of FTD in men?

References

[Chen X et al, Microglial activation and neuroinflammation in frontotemporal dementia: a systematic review (2023)](https://pubmed.ncbi.nlm.nih.gov/37998012/)

[Liddell JR et al, Are microglia the mastermind in neurodegenerative diseases? (2019)](https://pubmed.ncbi.nlm.nih.gov/31058550/)

[Heneka MT et al, Neuroinflammatory aspects of Alzheimer's disease and frontotemporal dementia (2015)](https://pubmed.ncbi.nlm.nih.gov/25640385/)

[Gomez-Nicola D et al, Microglial dynamics in human brain disorders: from development to disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32440070/)

[Zhou J et al, Microglial correlates of frontotemporal dementia: from neurodevelopment to degeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/36439182/)

[Sudomino T et al, Complement activation and synaptic pruning in the FTD brain (2023)](https://pubmed.ncbi.nlm.nih.gov/37542477/)

[Williams ET et al, Complement in neurodegenerative disease: from development to therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37379856/)

[Hickman SE et al, Microglial dysfunction in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38200419/)

[Key hem et al, TREM2 deficiency exacerbates neuroinflammation in a mouse model of FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/36970968/)

[Zhang B et al, TREM2 deficiency reduces microglial surveillance of synapses and increases synaptic pathology in FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38520928/)

[Chen C et al, Cytokine and chemokine profiles in frontotemporal dementia: a systematic review and meta-analysis (2023)](https://pubmed.ncbi.nlm.nih.gov/37149956/)

[Sweeney MD et al, Blood-brain barrier dysfunction in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31406246/)

[Erlich SS et al, Astrocyte reactivity in frontotemporal dementia (2023)](https://pubmed.ncbi.nlm.nih.gov/36946218/)

[Bodea LG et al, Neonatal microglia loss causes early-onset memory deficits (2018)](https://pubmed.ncbi.nlm.nih.gov/30523151/)

[Bozza A et al, Systemic inflammation and blood-brain barrier disruption in FTD (2023)](https://pubmed.ncbi.nlm.nih.gov/36879253/)

[Miller KL et al, Microglial states in frontotemporal dementia: single-cell transcriptomics reveal diversity (2023)](https://pubmed.ncbi.nlm.nih.gov/37607436/)

[Liddell JR et al, TREM2 in FTD: microglial orchestration of neuronal damage (2024)](https://pubmed.ncbi.nlm.nih.gov/38168912/)

[Sudomino T et al, Complement-mediated synapse elimination in GRN-FTD and C9orf72-FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38732929/)

[Parker SE et al, Inflammatory phenotypes of microglia in frontotemporal dementia subtypes (2024)](https://pubmed.ncbi.nlm.nih.gov/38503412/)

[Gomez-Nicola D et al, Microglial depletion delays neurodegeneration in a mouse model of FTD (2024)](https://pubmed.ncbi.nlm.nih.gov/38653792/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1
[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — 0.71 · Target: HSPA1A
[PARP1 Inhibition Therapy](/hypothesis/h-69919c49) — 0.67 · Target: PARP1
[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Arginine Methylation Enhancement Therapy](/hypothesis/h-19003961) — 0.65 · Target: PRMT1
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[RNA Granule Nucleation Site Modulation](/hypothesis/h-fffd1a74) — 0.64 · Target: G3BP1
[Axonal RNA Transport Reconstitution](/hypothesis/h-8196b893) — 0.63 · Target: HNRNPA2B1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving Neuroimmune Dysfunction in Frontotemporal Dementia discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-neuroimmune-dysfunction-ftd

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-neuroimmune-dysfunction-ftd
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-367e9cea18e1
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-neuroimmune-dysfunction-ftd'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

60

Outgoing

133

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neuroimmune Dysfunction in Frontotemporal Dementia

Neuroimmune Dysfunction in Frontotemporal Dementia

Overview

The Microglial Landscape in FTD

Microglial Activation States

Neuroimmune Dysfunction in Frontotemporal Dementia

Overview

The Microglial Landscape in FTD

Microglial Activation States

TREM2 in FTD Microglial Dysfunction

Microglial Synaptic Pruning in FTD

Complement System Dysregulation

Complement Cascade in the FTD Brain

Therapeutic Implications of Complement Dysregulation

Astrocyte Dysfunction

Reactive Astrogliosis in FTD

Astrocyte-Neuron Metabolic Coupling

Cytokine and Chemokine Profile in FTD

Peripheral and CNS Cytokine Levels

NLRP3 Inflammasome Activation

Blood-Brain Barrier Dysfunction

BBB Disruption in FTD

Perivascular Immune Cell Infiltration

Neuroinflammation Across FTD Genetic Subtypes

GRN (Progranulin) Mutations

C9orf72 Repeat Expansions

MAPT Mutations

FUS Mutations

Neuroimmune Mechanisms: Pathway Diagram

Biomarkers of Neuroimmune Dysfunction

PET Imaging

Fluid Biomarkers

Therapeutic Strategies Targeting Neuroimmune Dysfunction

Complement Inhibitors

Microglial Modulation

Anti-inflammatory Approaches

Astrocyte-Targeted Therapies

Research Gaps

See Also

References

Related Hypotheses

Pathway Diagram

💬 Discussion